The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Uterine Fibroids-Global Market Insights and Sales Trends 2024
Synopsis
Uterine fibroids (myoma) are benign (non-cancerous) lumps that grow in the muscular wall of the uterus. They vary in sizes, from minute (a quarter of an inch) to the size of more than16 centimeters. The incidence of uterine fibroid is about 20%–40% in women during their reproductive ages. Occasionally, these fibroids swell up and make the uterus to grow like full visible pregnancy. Mostly, there are more than one fibroid in the uterus. However, fibroids do not always cause any symptoms, their location, and size results to difficulties for few women, including pain, discomfort and heavy bleeding. Uterine fibroid can be of different types such as intramural fibroids, subserosal fibroids, pedunculated fibroids and submucosal fibroids. There can be many reasons for uterine fibroid formation but genetic problems hormonal imbalance and other factors are predominant. The cardinal symptoms of uterine fibroids are heavy menstrual bleeding, abdominal pain, excessive uterine bleeding, increased urinary frequency, anaemia and infertility. Apart from physical morbidity, uterine fibroid ailment is a frequent cause of significant damage of quality of life and a major reason for hysterectomy. Therapy has traditionally based on two extremes: medicinal management, comprising progestins, oral contraceptives and GnRH agonists and surgical management, including myomectomy, hysterectomy, and ablation for most serious cases.
The global Uterine Fibroids market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Uterine Fibroids in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers, Diagnostic Centers and Others, are propelling Uterine Fibroids market. Non-Hormonal Treatment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hormonal Treatment segment is estimated at % CAGR for the next seven-year period.
Patients suffering from uterine fibroid problem represent an undeserved and huge market due to the absence of satisfactory medical treatments. Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Uterine Fibroids, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Uterine Fibroids market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Uterine Fibroids market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Uterine Fibroids sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Uterine Fibroids covered in this report include Boston Scientific, Cooper Surgical, C.R. Bard, F. Hoffmann-La Roche, GE Healthcare, Karl Storz Endoscopy, Richard Wolf Medical Instruments, Siemens Medical Solutions and AbbVie, etc.
The global Uterine Fibroids market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Boston Scientific
Cooper Surgical
C.R. Bard
F. Hoffmann-La Roche
GE Healthcare
Karl Storz Endoscopy
Richard Wolf Medical Instruments
Siemens Medical Solutions
AbbVie
AstraZeneca
Bayer
Eli Lilly
GlaxoSmithKline Pharmaceuticals
Pfizer
Johnson & Johnson
Novartis
Global Uterine Fibroids market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Uterine Fibroids market, Segment by Type:
Non-Hormonal Treatment
Hormonal Treatment
Global Uterine Fibroids market, by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Uterine Fibroids companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Uterine fibroids (myoma) are benign (non-cancerous) lumps that grow in the muscular wall of the uterus. They vary in sizes, from minute (a quarter of an inch) to the size of more than16 centimeters. The incidence of uterine fibroid is about 20%–40% in women during their reproductive ages. Occasionally, these fibroids swell up and make the uterus to grow like full visible pregnancy. Mostly, there are more than one fibroid in the uterus. However, fibroids do not always cause any symptoms, their location, and size results to difficulties for few women, including pain, discomfort and heavy bleeding. Uterine fibroid can be of different types such as intramural fibroids, subserosal fibroids, pedunculated fibroids and submucosal fibroids. There can be many reasons for uterine fibroid formation but genetic problems hormonal imbalance and other factors are predominant. The cardinal symptoms of uterine fibroids are heavy menstrual bleeding, abdominal pain, excessive uterine bleeding, increased urinary frequency, anaemia and infertility. Apart from physical morbidity, uterine fibroid ailment is a frequent cause of significant damage of quality of life and a major reason for hysterectomy. Therapy has traditionally based on two extremes: medicinal management, comprising progestins, oral contraceptives and GnRH agonists and surgical management, including myomectomy, hysterectomy, and ablation for most serious cases.
The global Uterine Fibroids market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Uterine Fibroids in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers, Diagnostic Centers and Others, are propelling Uterine Fibroids market. Non-Hormonal Treatment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hormonal Treatment segment is estimated at % CAGR for the next seven-year period.
Patients suffering from uterine fibroid problem represent an undeserved and huge market due to the absence of satisfactory medical treatments. Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Uterine Fibroids, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Uterine Fibroids market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Uterine Fibroids market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Uterine Fibroids sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Uterine Fibroids covered in this report include Boston Scientific, Cooper Surgical, C.R. Bard, F. Hoffmann-La Roche, GE Healthcare, Karl Storz Endoscopy, Richard Wolf Medical Instruments, Siemens Medical Solutions and AbbVie, etc.
The global Uterine Fibroids market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Boston Scientific
Cooper Surgical
C.R. Bard
F. Hoffmann-La Roche
GE Healthcare
Karl Storz Endoscopy
Richard Wolf Medical Instruments
Siemens Medical Solutions
AbbVie
AstraZeneca
Bayer
Eli Lilly
GlaxoSmithKline Pharmaceuticals
Pfizer
Johnson & Johnson
Novartis
Global Uterine Fibroids market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Uterine Fibroids market, Segment by Type:
Non-Hormonal Treatment
Hormonal Treatment
Global Uterine Fibroids market, by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Uterine Fibroids companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Uterine Fibroids
1.1 Uterine Fibroids Market Overview
1.1.1 Uterine Fibroids Product Scope
1.1.2 Uterine Fibroids Market Status and Outlook
1.2 Global Uterine Fibroids Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Uterine Fibroids Market Size by Region (2018-2029)
1.4 Global Uterine Fibroids Historic Market Size by Region (2018-2023)
1.5 Global Uterine Fibroids Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Uterine Fibroids Market Size (2018-2029)
1.6.1 North America Uterine Fibroids Market Size (2018-2029)
1.6.2 Europe Uterine Fibroids Market Size (2018-2029)
1.6.3 Asia-Pacific Uterine Fibroids Market Size (2018-2029)
1.6.4 Latin America Uterine Fibroids Market Size (2018-2029)
1.6.5 Middle East & Africa Uterine Fibroids Market Size (2018-2029)
2 Uterine Fibroids Market by Type
2.1 Introduction
2.1.1 Non-Hormonal Treatment
2.1.2 Hormonal Treatment
2.2 Global Uterine Fibroids Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Uterine Fibroids Historic Market Size by Type (2018-2023)
2.2.2 Global Uterine Fibroids Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Uterine Fibroids Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Uterine Fibroids Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Uterine Fibroids Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Uterine Fibroids Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Uterine Fibroids Revenue Breakdown by Type (2018-2029)
3 Uterine Fibroids Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Centers
3.1.3 Diagnostic Centers
3.1.4 Others
3.2 Global Uterine Fibroids Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Uterine Fibroids Historic Market Size by Application (2018-2023)
3.2.2 Global Uterine Fibroids Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Uterine Fibroids Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Uterine Fibroids Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Uterine Fibroids Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Uterine Fibroids Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Uterine Fibroids Revenue Breakdown by Application (2018-2029)
4 Uterine Fibroids Competition Analysis by Players
4.1 Global Uterine Fibroids Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Uterine Fibroids as of 2022)
4.3 Date of Key Players Enter into Uterine Fibroids Market
4.4 Global Top Players Uterine Fibroids Headquarters and Area Served
4.5 Key Players Uterine Fibroids Product Solution and Service
4.6 Competitive Status
4.6.1 Uterine Fibroids Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Boston Scientific
5.1.1 Boston Scientific Profile
5.1.2 Boston Scientific Main Business
5.1.3 Boston Scientific Uterine Fibroids Products, Services and Solutions
5.1.4 Boston Scientific Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.1.5 Boston Scientific Recent Developments
5.2 Cooper Surgical
5.2.1 Cooper Surgical Profile
5.2.2 Cooper Surgical Main Business
5.2.3 Cooper Surgical Uterine Fibroids Products, Services and Solutions
5.2.4 Cooper Surgical Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.2.5 Cooper Surgical Recent Developments
5.3 C.R. Bard
5.3.1 C.R. Bard Profile
5.3.2 C.R. Bard Main Business
5.3.3 C.R. Bard Uterine Fibroids Products, Services and Solutions
5.3.4 C.R. Bard Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.3.5 F. Hoffmann-La Roche Recent Developments
5.4 F. Hoffmann-La Roche
5.4.1 F. Hoffmann-La Roche Profile
5.4.2 F. Hoffmann-La Roche Main Business
5.4.3 F. Hoffmann-La Roche Uterine Fibroids Products, Services and Solutions
5.4.4 F. Hoffmann-La Roche Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.4.5 F. Hoffmann-La Roche Recent Developments
5.5 GE Healthcare
5.5.1 GE Healthcare Profile
5.5.2 GE Healthcare Main Business
5.5.3 GE Healthcare Uterine Fibroids Products, Services and Solutions
5.5.4 GE Healthcare Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.5.5 GE Healthcare Recent Developments
5.6 Karl Storz Endoscopy
5.6.1 Karl Storz Endoscopy Profile
5.6.2 Karl Storz Endoscopy Main Business
5.6.3 Karl Storz Endoscopy Uterine Fibroids Products, Services and Solutions
5.6.4 Karl Storz Endoscopy Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.6.5 Karl Storz Endoscopy Recent Developments
5.7 Richard Wolf Medical Instruments
5.7.1 Richard Wolf Medical Instruments Profile
5.7.2 Richard Wolf Medical Instruments Main Business
5.7.3 Richard Wolf Medical Instruments Uterine Fibroids Products, Services and Solutions
5.7.4 Richard Wolf Medical Instruments Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.7.5 Richard Wolf Medical Instruments Recent Developments
5.8 Siemens Medical Solutions
5.8.1 Siemens Medical Solutions Profile
5.8.2 Siemens Medical Solutions Main Business
5.8.3 Siemens Medical Solutions Uterine Fibroids Products, Services and Solutions
5.8.4 Siemens Medical Solutions Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.8.5 Siemens Medical Solutions Recent Developments
5.9 AbbVie
5.9.1 AbbVie Profile
5.9.2 AbbVie Main Business
5.9.3 AbbVie Uterine Fibroids Products, Services and Solutions
5.9.4 AbbVie Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.9.5 AbbVie Recent Developments
5.10 AstraZeneca
5.10.1 AstraZeneca Profile
5.10.2 AstraZeneca Main Business
5.10.3 AstraZeneca Uterine Fibroids Products, Services and Solutions
5.10.4 AstraZeneca Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.10.5 AstraZeneca Recent Developments
5.11 Bayer
5.11.1 Bayer Profile
5.11.2 Bayer Main Business
5.11.3 Bayer Uterine Fibroids Products, Services and Solutions
5.11.4 Bayer Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.11.5 Bayer Recent Developments
5.12 Eli Lilly
5.12.1 Eli Lilly Profile
5.12.2 Eli Lilly Main Business
5.12.3 Eli Lilly Uterine Fibroids Products, Services and Solutions
5.12.4 Eli Lilly Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.12.5 Eli Lilly Recent Developments
5.13 GlaxoSmithKline Pharmaceuticals
5.13.1 GlaxoSmithKline Pharmaceuticals Profile
5.13.2 GlaxoSmithKline Pharmaceuticals Main Business
5.13.3 GlaxoSmithKline Pharmaceuticals Uterine Fibroids Products, Services and Solutions
5.13.4 GlaxoSmithKline Pharmaceuticals Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.13.5 GlaxoSmithKline Pharmaceuticals Recent Developments
5.14 Pfizer
5.14.1 Pfizer Profile
5.14.2 Pfizer Main Business
5.14.3 Pfizer Uterine Fibroids Products, Services and Solutions
5.14.4 Pfizer Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.14.5 Pfizer Recent Developments
5.15 Johnson & Johnson
5.15.1 Johnson & Johnson Profile
5.15.2 Johnson & Johnson Main Business
5.15.3 Johnson & Johnson Uterine Fibroids Products, Services and Solutions
5.15.4 Johnson & Johnson Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.15.5 Johnson & Johnson Recent Developments
5.16 Novartis
5.16.1 Novartis Profile
5.16.2 Novartis Main Business
5.16.3 Novartis Uterine Fibroids Products, Services and Solutions
5.16.4 Novartis Uterine Fibroids Revenue (US$ Million) & (2018-2023)
5.16.5 Novartis Recent Developments
6 North America
6.1 North America Uterine Fibroids Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Uterine Fibroids Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Uterine Fibroids Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Uterine Fibroids Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Uterine Fibroids Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Uterine Fibroids Market Dynamics
11.1 Uterine Fibroids Industry Trends
11.2 Uterine Fibroids Market Drivers
11.3 Uterine Fibroids Market Challenges
11.4 Uterine Fibroids Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
